Ipragliflozin

Bioss Antibodies

Ipragliflozin [761423-87-4]

16

Research Use Only

>98%

Ipragliflozin is an orally active, highly potent sodium glucose co-transporter 2 (SGLT-2) inhibitor (IC50 = 7.4nM), selective over SGLT-1, 3, 4, 5 and 6. SGLT-2 is one subtype of SGLTs found almost exclusively in the proximal tubules of nephronic components in kidneys, playing a key role in the re-uptake of glucose in the proximal tubule of the kidneys. Inhibition of SGLT-2 reduces blood glucose by blocking renal glucose reabsorption and thereby increasing urinary glucose excretion (UGE). Anti-diabetic and anti-obesity agent. Shown to improve glycemic control and reduce body weight, furthermore, lowering hypoglycemic risk and abdominal symptoms. SGLT-2 inhibitors are likely to improve beta-cell function and insulin sensitivity and restore glucose homeostasis. Attenuates non-alcoholic steatohepatitis (NASH) development.

-20°C

51202000